Targeting SARS-CoV-2-Platelet.....pdf (982.22 kB)
Download fileTargeting SARS-CoV-2-platelet interactions in COVID-19 and vaccine-related thrombosis.
It is clear that COVID-19 is more than a pneumonia and is associated with a coagulopathy and multi-organ failure. While the use of anti-coagulants does reduce the incidence of pulmonary emboli, it does not help with survival. This suggests that the coagulopathy is more likely to be platelet-driven rather than thrombin-driven. There is significant evidence to suggest that SARS-CoV-2 virions directly interact with platelets to trigger activation leading to thrombocytopenia and thrombosis. I propose a model of multiple interactions between SARS-CoV-2 and platelets that has many similarities to that with Staphylococcus aureus and Dengue virus. As platelet activation and thrombosis are major factors in poor prognosis, therapeutics that target the platelet-SARS-CoV-2 interaction have potential in treating COVID-19 and other virus infections.
History
Comments
The original article is available at https://www.frontiersin.orgPublished Citation
Cox D. Targeting SARS-CoV-2-platelet interactions in COVID-19 and vaccine-related thrombosis. Front Pharmacol. 2021;12:708665.Publication Date
5 July 2021External DOI
PubMed ID
34290613Department/Unit
- School of Pharmacy and Biomolecular Sciences
Research Area
- Immunity, Infection and Inflammation
- Vascular Biology
Publisher
Frontiers Media SAVersion
- Published Version (Version of Record)
Usage metrics
Categories
Keywords
Pharmacology and Pharmaceutical SciencesFcgamma receptor IIASARS-CoV-2bacteriaimmunothrombosisplateletssepsisvaccine thrombosisVirusPandemicsCoronavirusVaccine-Related ThrombosisCOVID-19SARS-CoV-2-Associated IllnessesTargeting PlateletsInfectious DiseasesPharmaceutical SciencesRespiratory DiseasesCardiology (incl. Cardiovascular Diseases)